

Supplementary Table 1. **Factors of unTACEable** progression in patients treated with TACE plus sorafenib and TACE alone.

	TACE plus sorafenib (n=80)	TACE alone (n=76)
No progression	30	27
Progression pattern	50	49
Intrahepatic lesion growth>25% or TACE refractoriness	24	31
Vascular Invasion	11	8
Extrahepatic spread	13	8
Deterioration of liver function to Child-Pugh C	2	2

Numbers are expressed as number of patients.